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Abstract 
 
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is 
developing Guidelines for Allergen Immunotherapy (AIT) for IgE-mediated Food Allergy. To 
inform the development of clinical recommendations, we sought to critically assess evidence on 
the effectiveness, safety and cost-effectiveness of AIT in the management of food allergy. 
 
Methods: We undertook a systematic review and meta-analysis that involved searching nine 
international electronic databases for randomized controlled trials (RCTs) and non-randomized 
studies (NRS). Eligible studies were independently assessed by two reviewers against pre-defined 
eligibility criteria. The quality of studies was assessed using the Cochrane Risk of Bias tool for 
RCTs and the Cochrane ACROBAT-NRS tool for quasi-RCTs. Random-effects meta-analyses 
were undertaken, with planned subgroup and sensitivity analyses. 
 
Results: We identified 1814 potentially relevant papers from which we selected 31 eligible 
studies, comprising of 25 RCTs and six NRS, studying a total of 1259 patients. Twenty-five trials 
evaluated oral immunotherapy (OIT), five studies investigated sublingual immunotherapy (SLIT) 
and one study evaluated epicutaneous immunotherapy (EPIT). The majority of these studies 
were in children. Twenty-seven studies assessed desensitization and nine studies investigated 
sustained unresponsiveness post-discontinuation of AIT.  Meta-analyses demonstrated a 
substantial benefit in terms of desensitization (risk ratio (RR)=0.19, 95%CI 0.12, 0.29) and 
sustained unresponsiveness (RR=0.20, 95%CI 0.10, 0.59).  Only one study reported on disease-
specific quality of life (QoL), which reported no comparative results between OIT and control 
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group. Meta-analyses revealed that the risk of experiencing a systemic adverse reaction was 
higher in those receiving AIT, with a more marked increase in the risk of local adverse reactions. 
Sensitivity analysis excluding those studies judged to be at high risk of bias demonstrated the 
robustness of summary estimates of effectiveness and safety of AIT for food allergy.  None of 
the studies reported data on health economic analyses. 
 
Conclusions:  AIT may be effective in raising the threshold of reactivity to a range of foods in 
children with IgE-mediated food allergy whilst receiving (i.e. desensitization) and post-
discontinuation of AIT.  It is however associated with a modest increased risk in serious systemic 
adverse reactions and a substantial increase in minor local adverse reactions. More data are 
needed in relation to adults, the impact on QoL and the cost-effectiveness of AIT. 
 
Keywords: Allergen, allergen immunotherapy, desensitization, food allergy, safety, sensitization, 
sustained unresponsiveness. 
 
BACKGROUND 
Food allergy  may result in considerable morbidity and, in some cases, mortality.(1) 
Epidemiological studies have demonstrated that the prevalence and severity of food allergy may 
be increasing, particularly in children.(2-8) Food allergies can be divided into IgE-mediated acute 
allergic reactions manifesting as urticaria, vomiting, wheezing and anaphylaxis, and non-IgE-
mediated food allergy which results from delayed, cell-mediated reactions. This systemic review 
is focused on IgE-mediated reactions. 
 
Food allergies can be associated with significant reduction in disease specific quality of life (QoL) 
– both of individuals who suffer from food allergy and their family members.(9, 10) At present, 
avoidance measures are the cornerstone of  management.(11) Difficulties in avoiding responsible 
food allergens can however result in accidental exposure and the risk of triggering potentially 
life-threatening anaphylaxis. Of concern is the increasing numbers of people being seen in 
emergency departments or who are hospitalized because of food-induced anaphylaxis.(12, 13) 
Individuals with food allergy therefore need to carry adrenaline (epinephrine) auto-injectors in 
order to self-manage anaphylaxis. This approach is however perceived as restrictive and still 
leaves patients at risk if accidental exposure occurs.(2, 7, 8)  
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Allergen immunotherapy (AIT) has been used for over a century to treat those with food 
allergy.(14)  It involves repeated administration of gradually increasing doses of the antigens to 
which individuals are allergic in the hope of allowing safe exposure to the food(s) in question. 
Whilst AIT has become an established treatment regimen in relation to the management of, for 
example, pollen and insect venom allergy,(15) it has yet to become established in the routine 
management of food allergy. 
 
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of 
developing the EAACI Guidelines for AIT, and this systematic review and meta-analysis is one 
of five inter-linked assessments of the current evidence base in relation to evaluating AIT for the 
treatment of food allergy, allergic rhinoconjunctivitis, venom allergy, allergic asthma and allergy 
prevention, which will be used to inform development of clinical recommendations. The focus 
of this review, which builds on our previous related reviews,(16, 17) is to assess the effectiveness, 
safety and cost-effectiveness of AIT in the management of IgE-mediated food allergy. 
 
METHODS 
Details of the methods employed in this review, including search terms and filters, databases 
searched, inclusion and exclusion criteria, data extraction and quality appraisal, have been 
previously reported.(18) We therefore confine ourselves here to a synopsis of the methods 
employed. 
 
Search strategy 
Nine international databases were searched for published material: Cochrane Library, which 
includes CENTRAL [Trials, Methods studies, Health Technology Assessments (HTA), 
Economic Evaluation database (EED)]; MEDLINE, EMBASE, ISI Web of Science, TRIP and 
CINAHL. The search strategy was developed on OVID MEDLINE and then adapted for the 
other databases (see Supporting Information - Appendix 1, search strategies 1 and 2). Our 
database searches covered from inception to March 31, 2016. The bibliographies of all eligible 
studies were scrutinized to identify additional possible studies. No language restrictions were 
imposed and where necessary manuscripts were translated into English. 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Inclusion criteria 
Patient characteristics 
We focused on studies conducted on children and adults of any age with a clinician-diagnosed 
IgE-mediated food allergy to milk, eggs, peanuts, tree nuts and other foods with confirmation of 
allergic status through positive skin prick tests, specific-IgE and/or food challenge tests. 
 
Interventions of interest and comparators 
This review focused on AIT for different allergens, i.e. milk, eggs, tree nuts, peanuts and other 
foods, administered through the following routes: oral (OIT), sublingual (SLIT) and 
epicutaneous (EPIT). We were interested in studies comparing food allergy AIT with placebo or 
routine care (i.e. adrenaline auto-injector with or without antihistamines) or no treatment. 
 
Outcomes 
Our primary outcomes of interest were: 1) desensitization (i.e. the ability to safely consume 
foods containing the allergen in question while on AIT); 2) sustained unresponsiveness (i.e. the 
ability to safely consume foods containing the allergen in question after discontinuing AIT) at 
food challenge; and 3) changes in disease specific QoL using a validated instrument. Secondary 
outcome measures of interest were safety as assessed by local and systemic reactions in 
accordance with the World Allergy Organization’s (WAO) grading system of side-effects.(19, 20)  
 
 
Study designs 
We were interested in RCTs investigating the role of OIT, SLIT or EPIT in children and adults 
with IgE-mediated food allergy. However, given the likelihood that we would find only a limited 
number of RCTs, we also searched for non-randomized studies (NRS), these including non-
randomized controlled clinical trials (CCTs), controlled before-and-after (CBA) studies and 
interrupted time series (ITS) analyses.   
 
Study selection 
All references were uploaded into the systematic review software DistillerSR. Titles and abstracts 
of identified studies were checked and independently reviewed by two researchers (UN, SD). 
The full text of all potentially eligible studies were assessed for eligibility against the eligibility 
criteria (UN, SA). Any disagreements were resolved through discussion, with SD or AS 
arbitrating if agreement could not be reached. 
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Quality assessment strategy 
The quality of included RCTs  was independently assessed by two reviewers (UN, SA) using the 
methods detailed in section eight of the Cochrane Handbook for Systematic Reviews of 
Interventions.(21) Critical appraisal of quasi-RCTs, CCTs was undertaken using the Cochrane 
ACROBAT tool for NRS.(22)  An overall assessment of quality for each trial using these 
categories was arrived at through consensus discussion amongst reviewers. 
 
Data extraction, analysis and synthesis 
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two 
reviewers (UN, SA) and any discrepancies were resolved by discussion or, if agreement could not 
be reached, by arbitration by a third reviewer (SD or AS).  
 
Where possible and appropriate, data were synthesized using random-effects meta-analyses 
following the pre-specified analysis plan.  For the assessment of safety, as there were a number 
of studies with zero reported outcomes, in order to facilitate meta-analyses we expressed safety 
data as the risk of not experiencing a local or systemic reaction. All analyses were undertaken 
using the software Comprehensive Meta-Analysis (version 3). 
 
Sensitivity, subgroup analyses, and assessment for publication bias 
Sensitivity analyses were undertaken by focusing on results from double-blind RCTs.  Subgroup 
analyses were undertaken to compare: 
 Diagnosis of food allergy was confirmed by double-blind, placebo-controlled, food 
challenge (DBPCFC) versus without DBPCFC 
 Route of administration: OIT versus SLIT versus EPIT  
 Children (0-17 years) versus adults (≥18 years) 
 Type of AIT protocol: conventional versus rush 
 Allergens used for AIT. 
 
Where possible, publication bias was assessed through the creation of funnel plots in 
Comprehensive Meta-Analysis (version 3).   
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Registration and reporting of this systematic review 
This systematic review was conducted and reported in accordance with Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The protocol is 
registered in PROSPERO (International Prospective Register of Systematic Reviews) with 
registration number: CRD42016039384.  
 
RESULTS 
     Our searches identified 1814 potentially relevant papers, from which we identified 31 trials that 
satisfied our inclusion criteria studying a total of 1259 patients (Figure 1: PRISMA flow diagram). 
There were 25 RCTs (23-46)  and six NRS’, all of which were CCTs.(47-52)  Twenty-five of 
these trials investigated OIT(23-27, 30, 33, 35-50, 52), one epicutaneous immunotherapy 
(EPIT)(28)  and the remaining five investigated SLIT.(29, 31, 32, 34, 51) One report included 
two independent RCTs on cow’s milk (CMA) and hen’s egg (HEA).(39) Sixteen studies focused 
on CMA,(25, 35-37, 39-44, 47-51) 11 on HEA,(24, 26, 27, 30, 33, 38, 39, 41, 44, 50, 51) seven on 
peanut,(23, 32, 34, 45, 46, 50, 52) one hazelnut,(29) two peach,(31, 50) three apple,(41, 50, 51) 
three fish,(41, 50, 51) and two other studies focused on a  variety of food allergens including 
orange, corn, bean, lettuce,(50) wheat and bean(51) (see Table 1 and Supporting Information: 
Appendix 2, Table S1). The trials were undertaken in Italy (n=9), Spain (n=7), the USA (n=6), 
France (n=3), Australia (n=1), Finland (n=1), Germany (n=1), Iran (n=1), Korea (n=1), and the 
UK (n=1). 
 
Quality assessment 
Quality assessment of these studies revealed that eight of the RCTs were judged to be at low risk 
of bias;(24, 26, 32, 34, 36, 40, 45, 46) a further five RCTs  were judged as at unclear risk of 
bias,(28, 31, 33, 37, 43) and the remaining 12 RCTs(23, 25, 27, 29, 30, 35, 38, 39, 41, 42, 44)  
were judged to be at high risk of bias (see Supporting Information: Appendix 3, Table S2). The 
six CCTs(47-52)  were all judged to be at moderate risk of bias (see Supporting Information: 
Appendix 4, Table S3). 
 
Primary outcomes 
Desensitization 
Desensitization was assessed in 18 OIT RCTs(23-27, 33, 35-43, 45, 46)  and five OIT CCTs.(47-
51) There were also four SLIT RCTs(29, 31, 32, 34) and one SLIT CCT(51) that assessed 
desensitization. The efficacy of AIT was compared with placebo in 12 studies, eight of which 
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used OIT(24-26, 42, 43, 45, 46) and four of SLIT;(29, 31, 32, 34) the other 17 studies, all of OIT, 
employed routine care (i.e. food avoidance/strict elimination diet as the comparator).(27, 30, 33, 
35-39, 41, 44, 47-52)  
 
Meta-analysis was possible with data from 28 trials investigating a total of 1218 subjects; this 
revealed a substantial benefit with respect to desensitization: relative risk (RR)=0.19, 95%CI 
0.12, 0.29; see Figure 2(a).(23-27, 29-41, 43, 44, 46-52)  
 
Sensitivity analyses 
Sensitivity analysis of the 22 RCTs, excluding the six CCTs, also demonstrated a substantial 
benefit: RR=0.24, 95%CI 0.16, 0.37; see Figure 2(b).(23-27, 29-41, 43, 44, 46) A further 
sensitivity analysis excluding all trials judged to be at high risk of bias confirmed this substantial 
benefit: RR=0.15, 95%CI 0.09, 0.24; see Figure 2(c)(24, 26, 31-34, 36, 37, 40, 43, 46-52) A 
further sensitivity analysis excluding all trials (whether OIT or SLIT) judged to be at high risk of 
bias demonstrated a substantial average risk reduction (RR OIT=0.17, 95%CI 0.11, 0.26);(24, 26, 
33, 36, 37, 40, 43, 46-50) (RR SLIT=0.31, 95%CI 0.10, 0.98)(31, 32, 34) (see  Supplementary 
Materials: Appendix 5,  Figures S1 and S2).  
 
A final sensitivity analysis focusing on studies in which desensitization was confirmed by 
DBPCFC after OIT or SLIT also revealed substantial benefits (RR 0.19, 95%CI 0.12, 0.32; see 
Supplementary Materials: Appendix 5, Figure S3).(23, 25-27, 29-31, 35-41, 43, 44, 47-52)  
 
Subgroup analyses 
 Subgroup analysis based on the route of administration of AIT (OIT versus SLIT) 
revealed that both OIT (RR=0.17, 95%CI 0.10, 0.27; see Figure 3)(23-27, 30, 33, 35-41, 
43, 44, 46-50, 52) and SLIT were effective (RR=0.26, 95%CI 0.10, 0.64; see Figure 4).(29, 
31, 32, 34, 51) 
 A subgroup analysis based on the age of the population studied (children aged up to 18 
years old, adults ≥18 years old and mixed population that included subjects 0-55 years 
old) revealed a substantial average risk reduction only for children and mixed 
populations, but not for adults studies (RR, children’s studies=0.19, 95%CI 0.12, 
0.30)(23-27, 30, 32-41, 43, 44, 46-49) 
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  (RR, adults studies=0.56, 95%CI 0.23, 1.36)(29, 31) (RR, mixed population=0.04, 
95%CI 0.01, 0.19)(50-52) (see   Supplementary Materials: Appendix 5, Figures S4, S5 and 
S6). 
 Subgroup analysis based on the type of AIT protocol (conventional versus rush) also 
showed a substantial average risk reduction for both methods (RR, conventional 
protocol=0.12, 95%CI 0.07, 0.21);(23-27, 30, 32-35, 38, 40, 43, 44, 46, 47, 49-52) (RR, 
rush=0.43, 95%CI 0.27, 0.70)(29, 31, 36, 37, 39, 41, 48) (see  Supplementary Materials: 
Appendix 5, Figures S7 and S8). 
 Subgroup analyses of types of allergen demonstrated that in 14 trials investigating CMA, 
11 HEA and four peanut allergy OIT/SLIT substantially reduced the risk of 
desensitization to CMA, HEA and peanut allergy (RR CM=0.16, 95%CI 0.08, 0.32);(25, 
35-37, 39-41, 43, 44, 47-51) (RR HE=0.22, 95%CI 0.11, 0.44);(24, 26, 27, 30, 33, 38, 39, 
41, 44, 50, 51) (RR peanut=0.11, 95%CI 0.04, 0.31)(23, 32, 34, 46) (see Supplementary 
Materials: Appendix 5, Figures S9, S10 and S11. A sensitivity analysis of the 17 OIT and 
four SLIT RCTs found a substantial average risk reduction (RR OIT=0.23, 95%CI 0.14, 
0.38);(23-27, 30, 33, 35-41, 43, 44, 46) (RR SLIT=0.31, 95%CI 0.13, 0.76)(29, 31, 32, 34) 
(see Supplementary Materials: Appendix 5, Figures S12 and S13).  
 
The Funnel plot revealed evidence of potential publication bias with fewer smaller, negative 
studies than expected (see Figure 5).  
 
Sustained unresponsiveness post-discontinuation of AIT 
There were seven OIT RCTs,(24, 26, 30, 33, 42, 44, 45) and two OIT CCTs(48, 52)  that 
investigated the longer-term effects of AIT between  two weeks and 36 months after 
discontinuation of AIT (see Table 1 and Appendix 2: Table S1). Meta-analysis revealed the 
benefits of OIT (RR=0.20, 95%CI 0.07, 0.59)(24, 26, 30, 33, 44, 48) (see Figure 6). 
 
A sensitivity analysis focusing on only RCTs in which  sustained unresponsiveness was 
confirmed by DBPCFC after OIT or SLIT also revealed substantial benefits (RR 0.23, 95%CI 
0.07, 0.73; see Figure 7).(24, 26, 30, 33, 44)  
 
The Funnel plot also revealed evidence of potential publication bias with fewer smaller, negative 
studies than expected (see Figure 8).  
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Disease specific quality of life 
Only one OIT RCT reported disease-specific QoL of patients and their families.(23)  This study 
used a validated questionnaire for parents, the Food Allergy Quality of Life Questionnaire Parent 
Form (FAQLQ-PF) however no comparative results between OIT and the control group were 
reported at the end of the first phase of the study. Results are reported for the end of the second 
phase of the study at which time the control group had also received OIT.  
.  
Secondary Outcomes 
Safety 
Systemic reactions 
Data on the occurrence of systemic adverse reactions during AIT were available from 25  
trials.(23-27, 29-31, 33, 35, 36, 39, 40, 42-51) (Table 1). However, there were different formats of 
reporting systemic reactions between trials, and we were therefore only able to pool data from 
seven studies.(26, 29, 31, 35, 40, 46, 49) Meta-analyses of not experiencing a systemic reactions 
was higher in those receiving control: RR=1.09, 95%CI 1.00, 1.19) (see Figure 9).(26, 29, 31, 35, 
40, 46, 49). 
  
Subgroup analysis demonstrated that the risk of experiencing a systemic reactions was higher in 
those receiving AIT (RR of not experiencing a reaction in controls=1.16, 95%CI 1.03, 1.30).(26, 
35, 40, 46, 49) In contrast, data from two SLIT studies showed no difference between arms (RR 
of not experiencing a reaction in controls=0.98, 95%CI 0.85, 1.14)(29, 31) (see Supplementary 
Materials: Appendix 5, Figures S14 and S15 ).  
 
Sensitivity analysis excluding all trials judged to be at high risk of bias after OIT or SLIT  
demonstrated either a borderline difference  (RR of not experiencing a reaction in controls=1.10, 
95%CI 0.99, 1.23)(26, 31, 40, 46, 49) or a significant difference in the rate of systemic reactions 
between the two arms after OIT (RR of not experiencing a reaction in controls=1.17, 95%CI 
1.03, 1.33)(26, 40, 46, 49) (see  Supplementary Materials -Appendix 5, Figures S16 and S17).  
 
A subgroup analysis of CMA trials found that the risk of experiencing a systemic reactions was 
higher in the AIT arm (RR of not experiencing a reaction in controls=1.19, 95%CI 1.03, 1.37)(35, 
40, 49)  (see  Supplementary Materials: Appendix 5, Figure S18). Subgroup analysis of systemic 
reactions during OIT from five children’s studies to cow’s milk, egg or peanut showed a 
significant difference between the two arms, however the pooled data from the two studies with 
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adult populations using SLIT for peach or hazelnut allergy found no clear evidence of a 
difference in systemic reactions between the treatment arms and the control arms (RR of not 
experiencing a reaction in controls, children=1.16, 95%CI 1.03, 1.30);(26, 35, 40, 46, 49) (RR of 
not experiencing a reaction in controls, adult=0.98, 95% CI 0.85, 1.14)(29, 31) The lack of a 
significant effect in adults may reflect a lack of precision (as the point estimate suggests benefit), 
which in turn is a function of the paucity of large trials in adult populations. 
 (see Supplementary Materials: Appendix 5, Figures S19 and S20). 
 
Local reactions 
Data on occurrence of local adverse reactions during AIT (minor 
oropharyngeal/gastrointestinal/ perioral rash) were available from 28 trials.(23-31, 33, 35-51)  
(see Table 1). However, there were different formats of reporting reactions between trials, and 
we were therefore only able to pool data from 10 studies.  Meta-analyses of local reactions 
obtained from these 10 trials demonstrated that AIT was associated with an increased risk of 
local reactions (RR of not experiencing a reaction in controls 1.88, 95%CI 1.42, 2.48)(24, 26, 35, 
37-40, 49) (see Figure 10).   
 
Subgroup analysis of local adverse events demonstrated higher risk of reactions in those 
receiving OIT (RR of not experiencing a reaction in controls=1.78, 95%CI 1.35, 2.33)(24, 26, 37-
40, 49) (see Supplementary Materials: Appendix 5, Figure S21). A further sensitivity analysis 
excluding all trials judged to be at high risk of bias also showed an increased risk of local 
reactions in the treatment arms compared with the control arms (RR of not experiencing a 
reaction in controls=2.58, 95%CI 1.37, 4.89)(24, 26, 37, 40, 49) (see Supplementary Materials: 
Appendix 5, Figure S22). Local reactions during OIT from only RCTs subgroup analysis 
demonstrated higher risk of local reactions in the AIT group (RR of not experiencing a reaction 
in controls=1.71, 95%CI 1.31, 2.24)(24, 26, 35, 37-40) (see Supplementary Materials- Appendix 
5, Figure S23). Another subgroup analysis of local reactions during OIT for CMA from either 
RCTs and CCTs or only RCTs also demonstrated increased risk of having local reactions in the 
AIT group (from RCTs and CCTs, RR of not experiencing a reaction in controls=2.70, 95%CI 
1.33, 5.47);(35, 37, 39, 40, 49) (from RCTs, RR of not experiencing a reaction in controls=2.36, 
95%CI 1.13, 4.96)(35, 37, 39, 40) (see Supplementary Materials: Appendix 5, Figures S24 and 
S25). Local reactions during OIT for HEA also found an increased risk of local reactions in the 
AIT arm (RR of not experiencing a reaction in controls=1.55, 95%CI 1.09, 2.22)(24, 26, 38, 39) 
(see Supplementary Materials: Appendix 5, Figure S26). 
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The effect of the AIT protocol (conventional versus rush) on the occurrence of local reactions 
during the treatment was available only from OIT trials. Both, conventional and rush AIT 
protocols demonstrated an increased risk of local reactions in the treatment arm compared with 
the controls (RR of not experiencing a reaction in controls, conventional=2.58, 95% CI 1.46, 
4.55)(24, 26, 35, 38, 40, 49) (RR of not experiencing a reaction in controls, rush=1.39, 95% CI 
1.00, 1.94)(37, 39)(see Supplementary Materials: Appendix 5, Figures S27 and S28). 
 
Health economic analysis 
None of the studies reported data on cost-effectiveness.  
 
DISCUSSION 
Summary of main findings 
This systematic review and meta-analysis has found evidence that AIT may be effective in raising 
the threshold of reactivity to a range of foods in patients with IgE-mediated food allergy whilst 
receiving (i.e. desensitization) and post-discontinuation of AIT. This evidence comes mainly 
from studies in children and it is therefore still unclear if AIT is effective for adults. Pooling of 
the safety data demonstrated an increased risk of local and systemic reactions with AIT. No 
fatalities were reported during AIT. Only one study assessed QoL,(23) which reported no 
comparative results between OIT and the control group. We found no data investigating the 
cost-effectiveness of AIT in patients with food allergy.   
 
Strengths and limitations of this work 
We believe that this systematic review is the most robust investigation undertaken to date to 
support the use of AIT in children and adults with food allergy.(53-60) A key strength of our 
systematic review was the comprehensiveness of the searches. We carefully identified and 
scrutinized the characteristics of all possible terms, including MeSH, EMTREE and free 
keywords for different types of food allergy and AIT. In addition, we encompassed all available 
bodies of evidence from all randomized and NRS, with a range of planned subgroup and 
sensitivity analyses. 
 
The main limitations of this systematic review stem from the heterogeneity of included 
populations, interventions, outcomes, diversity of AIT protocols and treatment modalities, and 
definition of outcomes (e.g. adverse reactions). Due to the heterogeneity of studies, the meta-
analyses need to be  interpreted with caution. In an attempt to account for this heterogeneity, we 
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undertook random-effects meta-analyses which produce more conservative assessments of 
benefits than would have been obtained using fixed-effects meta-analyses.  That said, this is an 
area that will warrant further exploration of the possible sources of heterogeneity in follow-on 
work.  We were also limited by the lack of data on long-term adverse outcomes (e.g. eosinophilic 
eesophagitis) and lack of data on cost-effectiveness. Studies which were published after our cut-
off date 31st March 2016 are not included in this review which may have provided additional 
evidence to support the effectiveness and safety of OIT.(61) 
 
Conclusions 
We found that AIT  may be effective in raising the threshold of reactivity to a range of foods in 
patients with IgE-mediated food allergy whilst receiving (i.e. desensitization) and post-
discontinuation of AIT, but was associated with an increased risk of local and systemic adverse 
events.  Future trials need in particular to investigate the effectiveness of AIT in adults, 
understand the impact of AIT on disease-specific QoL of patients and family members, and 
establish the cost-effectiveness of AIT for food allergy. 
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Figure 2(a). Risk ratios (RR) of desensitization following oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) v. controls (random-effects model) 
 
 
 
 
 
 
Study nam e Statistics for each study Events / Total Risk ratio and 95% CI
Risk Lower Upper Relative 
ratio lim it lim it Control Experim ental weight
Anagnostou 2014 0.017 0.001 0.277 0 / 46 24 / 39 1.96
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 1.99
Caminiti 2009 0.200 0.013 2.981 0 / 3 2 / 3 2.04
Caminiti 2015 0.011 0.000 1.952 0 / 14 16 / 17 0.65
Dello Lacono 2013 0.053 0.003 0.798 0 / 10 9 / 10 2.02
Enrique 2005 0.218 0.030 1.588 1 / 11 5 / 12 3.17
Escudero 2015 0.088 0.012 0.640 1 / 31 11 / 30 3.18
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 6.81
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 5.89
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 7.63
Garcia-Ara 2013 0.057 0.009 0.388 1 / 19 33 / 36 3.34
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 2.05
Lee 2013 0.045 0.003 0.688 0 / 12 14 / 16 2.01
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 1.94
Mansouri 2007 0.041 0.003 0.619 0 / 13 18 / 20 2.01
Martinez-Botas 2015 0.064 0.004 0.933 0 / 7 25 / 25 2.06
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 7.63
Meglio 2013 0.250 0.070 0.897 2 / 10 8 / 10 5.16
Morisset 2007a 0.656 0.467 0.923 18 / 32 24 / 28 8.75
Morisset 2007b 0.692 0.468 1.023 18 / 39 34 / 51 8.60
Paino 2010 0.048 0.003 0.746 0 / 15 10 / 15 1.98
Patriarca 1998 0.055 0.004 0.826 0 / 10 12 / 14 2.02
Patriarca 2003 0.039 0.003 0.597 0 / 16 45 / 59 2.00
Patriarca 2007 0.053 0.004 0.804 0 / 10 31 / 36 2.02
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 2.05
Staden 2007 0.963 0.431 2.150 7 / 21 9 / 26 7.04
Syed 2014 0.028 0.002 0.433 0 / 20 20 / 23 1.99
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 2.03
0.187 0.121 0.290 70 / 508 514 / 710
0.01 0.1 1 10 100
Favours experimental Favours control
Heterogeneity: Tau2 = 0.54; Chi2 = 72.74, df = 27 (P<0.0001); I2 = 63%; Test for overall effect: Z = 7.52 (P<0.0001)
Heterogeneity: τ2 = 0.54; χ2 = 72.74, df = 27 (P<0.0001); I2 = 63%; 
Test for overall effect: Z = 7.52 (P<0.0001) 
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Figure 2(b). Sensitivity analysis RR of desensitization after OIT or SLIT (only randomized controlled trials) 
 
 
 
 
 
 
Heterogeneity: τ2 = 0.43; χ2 = 55.61, df = 21 (P<0.0001); I2 = 62%; 
Test for overall effect: Z = 6.41 (P<0.0001) 
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Study name Statistics for each study Events / Total Risk ratio and 95% CI
Risk Lower Upper Relative 
ratio lim it lim it Control Experim ental weight
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 2.91
Caminiti 2015 0.036 0.002 0.557 0 / 14 16 / 17 2.94
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 14.08
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 11.31
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 16.96
Garcia-Ara 2013 0.057 0.009 0.388 1 / 19 33 / 36 5.32
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 3.02
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 2.83
Mansouri 2007 0.041 0.003 0.619 0 / 13 18 / 20 2.94
Martinez-Botas 2015 0.064 0.004 0.933 0 / 7 25 / 25 3.02
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 16.98
Paino 2010 0.048 0.003 0.746 0 / 15 10 / 15 2.90
Patriarca 2003 0.039 0.003 0.597 0 / 16 45 / 59 2.93
Patriarca 2007 0.053 0.004 0.804 0 / 10 31 / 36 2.97
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 3.01
Syed 2014 0.028 0.002 0.433 0 / 20 20 / 23 2.91
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 2.98
0.147 0.089 0.242 23 / 283 362 / 471
0.01 0.1 1 10 100
Favours experim ental Favours control
Fig. 2. (c) Sensitivity analysis RR of food allergy after OIT or SLIT (only LRB and URB studies) (random-effects model)
Heterogeneity: Tau2 = 0.27; Chi2 = 23.38, df = 16 (P<0.104); I2 = 31%; Test  for overall effect: Z = 7.53 (P<0.0001)
Figure 2(c). Sensitivity analysis RR of desensitization after OIT or SLIT (only LRB and URB studies) (random-effects model) 
Heterogeneity: τ2 = 0.27; χ2 = 23.38, df = 16 (P<0.104); I2 = 31%; 
Test for overall effect: Z = 7.53 (P<0.0001) 
Heterogeneity: τ2 = 0.27; χ2 = 23.38, df = 16 (P<0.104); I2 = 31%; 
Test for overall effect: Z = 7.53 (P<0.0001) 
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Study name Statistics for each study Events / Total Risk ratio and 95% CI
Risk Lower Upper Relative 
ratio lim it lim it Control Experim ental weight
Anagnostou 2014 0.017 0.001 0.277 0 / 46 24 / 39 2.51
Burks 2012 0.057 0.004 0.884 0 / 15 22 / 40 2.55
Caminiti 2009 0.200 0.013 2.981 0 / 3 2 / 3 2.61
Caminiti 2015 0.036 0.002 0.557 0 / 14 16 / 17 2.57
Dello Lacono 2013 0.053 0.003 0.798 0 / 10 9 / 10 2.58
Escudero 2015 0.088 0.012 0.640 1 / 31 11 / 30 4.00
Fuentes-Aparicio 2013 0.236 0.122 0.458 7 / 32 37 / 40 9.07
Garcia-Ara 2013 0.057 0.009 0.388 1 / 19 33 / 36 4.20
Lee 2013 0.045 0.003 0.688 0 / 12 14 / 16 2.57
Longo 2008 0.043 0.003 0.706 0 / 30 11 / 30 2.49
Mansouri 2007 0.041 0.003 0.619 0 / 13 18 / 20 2.57
Martinez-Botas 2015 0.064 0.004 0.933 0 / 7 25 / 25 2.63
Martorell 2011 0.259 0.134 0.501 7 / 30 27 / 30 9.07
Meglio 2013 0.250 0.070 0.897 2 / 10 8 / 10 6.33
Morisset 2007a 0.656 0.467 0.923 18 / 32 24 / 28 10.25
Morisset 2007b 0.692 0.468 1.023 18 / 39 34 / 51 10.10
Paino 2010 0.048 0.003 0.746 0 / 15 10 / 15 2.54
Patriarca 1998 0.055 0.004 0.826 0 / 10 12 / 14 2.58
Patriarca 2003 0.039 0.003 0.597 0 / 16 45 / 59 2.56
Skripak 2008 0.070 0.005 1.031 0 / 7 12 / 13 2.62
Staden 2007 0.963 0.431 2.150 7 / 21 9 / 26 8.43
Syed 2014 0.028 0.002 0.433 0 / 20 20 / 23 2.55
Varshney 2011 0.061 0.004 0.910 0 / 9 16 / 19 2.60
0.165 0.100 0.272 61 / 441 439 / 594
0.01 0.1 1 10 100
Favours experim ental Favours control
Fig. 3.  Risk ratios (RR) of persisting food allergy  as assessed  by double-blind placebo -controlled  food challenge  in OIT v. controls (random-effects model)
Heterogeneity: Tau2 = 0.61; Chi2 = 66.59, df = 22 (P<0.0001); I2 = 67%; Test  for overall effect: Z = 7.05 (P<0.0001)
Figure 3. Risk ratios (RR) of desensitization as assessed by double-blind placebo-controlled food challenge in OIT v. controls (random-effects 
model) 
Heterogeneity: τ2 = 0.27; χ2 = 23.38, df = 16 (P<0.104); I2 = 31%; 
Test for overall effect: Z = 7.53 (P<0.0001) 
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Study name Statistics for each study Events / Total Risk ratio and 95% CI
Risk Lower Upper Relative 
ratio limit limit Control Experimental weight
Enrique 2005 0.218 0.030 1.588 1 / 11 5 / 12 15.09
Fernandez-Rivas 2009 0.695 0.295 1.641 5 / 19 14 / 37 35.87
Fleischer 2013 0.214 0.073 0.632 3 / 20 14 / 20 30.23
Kim 2011 0.065 0.004 0.957 0 / 7 11 / 11 9.48
Patriarca 2007 0.053 0.004 0.804 0 / 10 31 / 36 9.33
0.257 0.103 0.641 9 / 67 75 / 116
0.01 0.1 1 10 100
Favours experimental Favours control
Fig. 4. Risk ratios (RR) of persisting food allergy as assessed by double-blind placebo-controlled food challenge in sublingual immunotherapy v . controls. (random-effects model)
Heterogeneity:  Tau2 = 0.41;  Chi2 = 6.80, df = 4 (P<0.147); I2 = 41% ; Test for ov erall effect:  Z = 2.91 (P<0.004)
Figure 4. Risk ratios (RR) of desensitization as assessed by double-blind placebo-controlled food challenge in SLIT v. controls (random-effects model) 
Heterogeneity: τ2 = 0.41; χ2 = 6.80, df = 4 (P<0.147); I2 = 41%; 
Test for overall effect: Z = 2.91 (P<0.004) 
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Figure 5. Funnel plot showing: Log risk ratios of persistent food allergy after OIT or SLIT 
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Figure 8. Funnel plot showing: Log risk ratios of persistent food allergy after OIT or SLIT (only RCTs) 
 
 
 
 
 
  
-5 -4 -3 -2 -1 0 1 2 3 4 5
0
1
2
3
S
ta
n
d
a
rd
 E
rr
o
r
Log risk ratio
Funnel Plot of Standard Error by Log risk ratio
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
  
Study name Statistics for each study Events / Total Risk ratio and 95% CI
Risk Lower Upper Relative 
ratio limit limit Control Experimental weight
Caminiti 2015 1.200 0.939 1.534 14 / 14 14 / 17 13.24
Enrigue 2005 0.992 0.770 1.277 10 / 11 11 / 12 12.48
Fernandez-Rivas 2009 0.974 0.812 1.167 17 / 19 34 / 37 24.24
Lee 2013 1.127 0.900 1.412 12 / 12 14 / 16 15.73
Mansouri 2007 1.227 0.961 1.568 13 / 13 16 / 20 13.30
Paino 2010 1.240 0.943 1.631 15 / 15 12 / 15 10.65
Varshney 2011 0.993 0.753 1.312 8 / 9 17 / 19 10.36
1.089 0.996 1.190 89 / 93 118 / 136
0.5 1 2
Favours experimental Favours control
Fig. 5. Safety data - absence of systemic reactions during OIT or SLIT for food allergy. RR, risk ratio (only RCTs) (random-effects model)
Heterogeneity: Tau2 = 0.0001; Chi2 = 4.87, df = 6 (P<0.56); I2 = 0%; Test for overall effect: Z = 1.86 (P<0.06)
Heterogeneity: τ2 = 0.0001; χ2 = 4.87, df = 6 (P<0.56); I2 = 0%; 
Test for overall effect: Z = 1.86 (P<0.06) 
Figure 9. Safety data – absence of systemic reactions during OIT or SLIT for food allergy. RR, risk ratio (random-effects model) 
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Study name Statistics for each study Events / Total Risk ratio and 95% CI
Risk Lower Upper Relative 
ratio limit limit Control Experimental weight
Burks 2012 3.556 1.897 6.665 12 / 15 9 / 40 8.64
Caminiti 2015 1.123 0.912 1.382 14 / 14 15 / 17 15.54
Dupont 2010 1.250 0.656 2.383 6 / 8 6 / 10 8.41
Lee 2013 6.000 1.576 22.844 9 / 12 2 / 16 3.13
Mansouri 2007 4.500 1.972 10.270 13 / 13 4 / 20 6.35
Martorell 2011 4.692 2.366 9.308 30 / 30 6 / 30 7.90
Meglio 2013 3.000 1.251 7.194 10 / 10 3 / 10 5.89
Morisset 2007a 1.085 0.941 1.251 31 / 32 25 / 28 16.39
Morisset 2007b 1.154 1.027 1.297 39 / 39 44 / 51 16.66
Paino 2010 1.824 1.141 2.914 15 / 15 8 / 15 11.09
1.801 1.387 2.340 179 / 188 122 / 237
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 6. Safety data - absence of local reactions during OIT or EPIT for food allergy. RR, risk ratio (random-effects model)
Heterogeneity: Tau2 = 0.10; Chi2 = 52.03, df = 9 (P<0.0001); I2 = 83%; Test for overall effect: Z = 4.41 (P<0.0001)
Figure 10. Safety data – absence of local reactions during OIT or EPIT for food allergy. RR, risk ratio (random-effects model) 
Heterogeneity: τ2 = 0.10; χ2 = 52.03, df = 9 (P<0.0001); I2 = 83%; 
Test for overall effect: Z = 4.41 (P<0.0001) 
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Table 1. Description of the included studies (n=31) 
 
 
Study  
(First author, year, country) 
Food allergen (s) Route AIT Comparator 
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(mandatory inclusion criteria) 
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Occurred AEs 
/ medication 
use 
Clinical 
history 
 SPT 
&/ or 
sIgE 
OFC SBPCFC DBPCFC SRs LRs 
RCT (n=25) 
Anagnostou, 2014, UK     X           X      X X X     X X   X X X 
Burks, 2012, USA   X             X    X   X X       X X   X X 
Caminiti, 2009, Italy X               X    X    X X     X X     X X 
Caminiti, 2015; Italy    X             X    X   X X     X X X   X X 
Dello Iacono, 2013, Italy   X             X      X X X     X X     X X 
Dupont, 2010, France X 
         
X X 
 
X X X   
 
X 
  
X X 
Enrique, 2005, Spain       X           X
ⱡ  X   X X     X X     X X 
Escudero, 2015, Spain   X             X      X X X     X   X   X X 
Fernandez-Rivas, 2009, Spain         X         X*  X   X X     X X     X X 
Fleischer, 2012, USA     X             X  X             X         
Fuentes-Aparicio, 2013, Spain   X             X      X X X X     X X   X X 
Kim, 2011, USA     X             X  X   X X       X         
Lee, 2013, Korea X               X      X X X     X X     X X 
Longo, 2008, Italy X               X      X X X     X X     X X 
Martorell, 2011, Spain  X               X      X X X     X X       X 
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/ medication 
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Meglio, 2013, Italy   X             X      X X X     X X       X 
Morisset, 2007, France^ X X             X      X X X   X   X     X X 
Pajno, 2010, Italy X               X    
 
X    X  X    
 
X  X      
 
X X  
Patriarca, 1998, Italy X X       X X   X      X X X     X X       X 
Salmivesi, 2012, Finland X               X    X   X X X     X X   X X 
Skripak, 2008, USA X               X    X     X     X X     X X 
Staden, 2007, Germany X X             X      X X X     X 
 
X   X X 
Tang, 2015, Australia     X           
X
¥   
 
X   X X     X X X   X X 
Varshney, 2011, USA     X           X    X   X X       X     X X 
CCT (n=6) 
García-Ara, 2013, Spain X               X      X X X X     X     X X 
Martınez-Botas, 2015, Spain X 
       
X 
 
 
 
X X X 
  
X X X 
 
X X 
Mansouri, 2007, Iran X                X       X X X    X X     X X 
Patriarca, 2003, Italy X X X   X X X X** X      X X X     X X     X X 
Patriarca, 2007, Italy X X 
 
  
 
X X X§ 
 
X*     X X X     X X     X X 
Syed, 2014, USA  
    X           X   
 
  X X X     X   X   
N
R NR 
 
AE, adverse event; AIT, allergen specific  immunotherapy; DR-QoL, disease related quality of life; LR, local reaction; NR, not reported; OIT, oral immunotherapy; OFC, open food challenge; SLIT, sublingual 
immunotherapy;  SR, systemic reaction. 
ⱡ sublingual-discharge technique 
*sublingual-swallow technique 
** orange, corn, bean, lettuce 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
§ wheat, bean 
¥ AIT and probiotics 
^ one report that included two independent randomized controlled trials on cows’ milk and hens’ eggs 
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Supplementary materials: Appendices 
 
Appendix 1: Search strategy 
 
Appendix 2: Table S1. Detailed characteristics of included studies 
 
Appendix 3: Table S2. Risk of bias assessment of RCTs 
 
Appendix 4: Table S3. Risk of bias assessment of CCTs 
 
Appendix 5: Additional forest plots (Figures S1 – S28) 
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